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Abstract
Introduction The cost of genetic testing and the limited
knowledge about the BRCA1 and BRCA2 genes in different
ethnic groups has limited its availability in medium- and low-
resource countries, including Malaysia. In addition, the
applicability of many risk-assessment tools, such as the
Manchester Scoring System and BOADICEA (Breast and
Ovarian Analysis of Disease Incidence and Carrier Estimation
Algorithm) which were developed based on mutation rates
observed primarily in Caucasian populations using data from
multiplex families, and in populations where the rate of breast
cancer is higher, has not been widely tested in Asia or in Asians
living elsewhere. Here, we report the results of genetic testing
for mutations in the BRCA1 or BRCA2 genes in a series of
families with breast cancer in the multi-ethnic population (Malay,
Chinese and Indian) of Malaysia.
Method A total of 187 breast cancer patients with either early-
onset breast cancer (at age ≤ 40 years) or a personal and/or
family history of breast or ovarian cancer were comprehensively
tested by full sequencing of both BRCA1 and BRCA2. Two
algorithms to predict the presence of mutations, the Manchester
Scoring System and BOADICEA, were evaluated.
Results Twenty-seven deleterious mutations were detected (14
in BRCA1 and 13 in BRCA2), only one of which was found in
two unrelated individuals (BRCA2 490 delCT). In addition, 47
variants of uncertain clinical significance were identified (16 in
BRCA1 and 31 in BRCA2). Notably, many mutations are novel
(13 of the 30 BRCA1 mutations and 24 of the 44 BRCA2). We
report that while there were an equal proportion of BRCA1 and
BRCA2 mutations in the Chinese population in our study, there
were significantly more BRCA2 mutations among the Malays. In
addition, we show that the predictive power of the BOADICEA
risk-prediction model and the Manchester Scoring System was
significantly better for BRCA1 than BRCA2, but that the overall
sensitivity, specificity and positive-predictive value was lower in
this population than has been previously reported in Caucasian
populations.
Conclusion Our study underscores the need for larger
collaborative studies among non-Caucasian populations to
validate the role of genetic testing and the use of risk-prediction
models in ensuring that the other populations in the world may
also benefit from the genomics and genetics era.
Introduction
The discovery of the BRCA1 and BRCA2 genes has trans-
formed the management of women who are at high risk of
developing breast and ovarian cancer. Diagnostically, it has
facilitated the accurate identification of women at risk of can-
cer; through screening and preventive measures, it has
reduced the incidence of cancer in such women [1], and per-
haps most importantly, exploitation of the knowledge that
these genes function in DNA repair has opened up avenues
for the development of new treatments for women with hered-
itary tumours [2].
BIC = Breast Cancer Information Core; BOADICEA = Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm; CI = con-
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Although predictive genetic testing is increasingly becoming a
part of clinical practice in many developed countries, the cost
of testing and the limited knowledge about the prevalence of
these genes in different ethnic groups has limited its availabil-
ity in medium- and low-resource countries [3,4]. There is rela-
tively little information about the BRCA1  and  BRCA2
mutations in Asia and among Asians living elsewhere and, to
date, no significant founder-effect mutation has been reported
[5,6]. Notably, although 60% of the world's population reside
in the Asian continent, and the Malays, Chinese and Indians
are three major Asian ethnic groups, relatively little is known
about the genetic predisposition to hereditary diseases and
the applicability of genetic testing in these diverse ethnic
groups [7-16].
Malaysia is a multi-ethnic country with a population of approx-
imately 23 million, comprising approximately 65% Malays and
other indigenous groups, approximately 26% Chinese and
approximately 8% Indian (Malaysia Housing and Population
Census 2000, Department of Statistics Malaysia). The Chi-
nese and Indians are largely first- or second-generation
migrants from southern China and southern India, while the
Malays and other minority indigenous groups are native to
South-East Asian countries including Malaysia and Indonesia.
In Malaysia, which may be described as a typical Asian coun-
try, breast cancer is characterised by: a lower age-standard-
ised rate (30 per 100,000 [17]); a proportionately higher
incidence of early-onset breast cancer (47% of new cases
occurred in women <50 years [17]); and an incomplete family
history or structure because of a lack of information about sec-
ond degree and further relatives, premature mortality and sig-
nificant dispersal of families. Taken together, studies in this
typical Asian multi-ethnic population provide an excellent
opportunity to understand genetic predisposition among the
different ethnic groups and among the different risk
categories.
Furthermore, in order to ensure that medicine based in genet-
ics can also be equitably implemented in low- and medium-
resource countries, it is critically important that there are cost-
effective mutation screening programmes. Currently, there is
little information about the effectiveness of these risk-assess-
ment tools in other ethnic populations, particularly in countries
with low age-standardised rate of breast cancer, which also
reflects the setting in many low- and medium-resource
countries.
Using a unique, ethnically diverse cohort of high-risk families,
we sought to: examine the significance of founder/recurrent
and novel rare BRCA1  and  BRCA2  mutations to familial
breast and ovarian cancer in the Malays, Chinese and Indian
populations of Malaysia; and compare the accuracy of the
Manchester Scoring System and the BOADICEA (Breast and
Ovarian Analysis of Disease Incidence and Carrier Estimation
Algorithm) risk-prediction models to predict pathogenic muta-
tions and particularly to discriminate at the 10% likelihood
level. Taken together, we wished to devise the most relevant
definition of individuals or families who would benefit from
mutation testing in this typical Asian country with a lower inci-
dence of breast cancer.
Materials and methods
Breast cancer cohort
The recruitment of Malaysian families with a high risk of breast
or ovarian cancer started in 2003 at the University Malaya
Medical Centre in Kuala Lumpur. Patients with breast cancer
were first approached by clinicians responsible for their care
to see if they would participate in a research study to deter-
mine the genetic factors which increase the risk of breast can-
cer in Malaysia. Thereafter, individuals interested in the project
were approached by a member of the research team who
explained to them the nature and objectives of the research
project. A total of 678 index cases were referred to our study
between January 2003 and December 2007. Index cases
signed a consent form and a blood sample was taken. A family
history was recorded and the pedigree analysed. Where pos-
sible, pathology reports were requested to confirm all diag-
noses of breast and ovarian cancers in the index case.
The study was approved by the ethics committee of University
Malaya Medical Centre.
Inclusion criteria for analysis of BRCA1 and BRCA2
All breast cancer patients in the cohort had: early-onset breast
cancer (≤ 40 years) and 1 or more additional cases of breast
cancer in first- or second-degree relatives; breast cancer (≥ 40
years) and two or more additional cases of breast cancer in
first- or second-degree relatives; bilateral breast cancer; or a
personal or family history of ovarian cancer. They were ana-
lysed for mutations in the BRCA1 and BRCA2 genes. In addi-
tion, approximately 50% of patients with only early-onset
breast cancer (≥ 40 years) with no significant family history or
breast cancer (≤ 40 years) and one additional case of breast
cancer in a first- or second-degree relative were also analysed.
Individuals were categorised based on self-reported race or
ethnicity. Of the 678 index cases, 187 were analysed for muta-
tions in the BRCA1 and BRCA2 genes (Table 1).
Mutation detection
Blood from index cases was separated into two 10 ml EDTA-
tubes and DNA was extracted using standard methods. Sam-
ples were analysed either at Genetic Technologies Laboratory
(Australia) or at Cancer Research Initiatives Foundation
(Malaysia) using direct DNA sequencing and multiple ligation
dependent probe amplification (MLPA), as previously
described [18]. Confirmation tests were performed on a sec-
ond blood sample. Naming and interpretation of sequence
analysis were performed as previously described and all
patients were classified as having a deleterious mutation if the
BRCA1 or BRCA2 protein terminated prematurely at least 10Available online http://breast-cancer-research.com/content/10/4/R59
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or 110 amino acids, respectively, from the C terminus. Genetic
variants of undetermined clinical significance (unclassified var-
iants) included missense mutations and mutations that
occurred in analysed intronic regions whose clinical signifi-
cance had not yet been determined. If more than one variant
was observed in a single analysis, the overall interpretation
was that of the most clinically significant mutation observed.
BOADICEA
The BOADICEA model allows for a polygenic modifier locus
effect in which several low-penetrance genes have joint
effects [19]. Family history information (including incidence of
breast, ovarian and other cancers, age at diagnosis and rela-
tionship to the proband) was collected and recorded by a
genetic counsellor or researcher. Breast cancer patients were
included in the BOADICEA analysis if they had more than one
primary cancer or if they had a family history of breast, ovarian,
pancreatic and/or prostate cancer in first-, second- or third-
degree relatives. Of the 187 individuals who were analysed for
mutations in BRCA1 and BRCA2, we excluded 42 individuals
(including three individuals with deleterious BRCA2  muta-
tions), all of whom had a single case of breast cancer and no
family history of breast, ovarian, pancreatic or prostate cancer
in first-, second- or third-degree relatives. The predicted likeli-
hood of carrying either a BRCA1 or BRCA2 mutation was
generated for each individual using BOADICEA risk estima-
tion on the internet (BOADICEA WEB APPLICATION v1.0).
Manchester Scoring System
We used the Manchester Scoring System to estimate the
probability of identifying mutations in BRCA1  and BRCA2
genes [20,21]. In brief, the scoring system was developed
using a combination of results from screening and family his-
tory of those with and without mutations, where a combined
score of 15 or more was proposed to correlate with a 10%
mutation probability. The exclusion criteria for BOADICEA
analysis was also applied to the Manchester Scoring System.
Results
Mutation testing outcome
A total of 1226 patients with breast cancer were treated at the
University Malaya Medical Centre between January 2003 and
December 2007, of which 678 individuals with breast cancer
from 674 families were recruited to the present study. Despite
rigorous efforts to identify women with a family history of
breast cancer, only 159 women were found to exhibit a family
history in a first- or second-degree relative (129 with one addi-
Table 1
Family characteristics
Total (n = 187) Malay (n = 44) Chinese (n = 118) Indian (n = 22) Others (n = 3)
No. (%) No. (%) No. (%) No. (%) No. (%)
Age of onset of breast cancer in index case (years)
20 to 29 14 (7) 3 (7) 10 (8) 1 (5) 0 (0)
30 to 39 64 (34) 21 (48) 36 (31) 6 (27) 1 (33)
40 to 49 49 (26) 8 (18) 35 (30) 5 (23) 1 (33)
≥ 50 60 (32) 12 (27) 37 (31) 10 (45) 1 (33)
Personal cancer history of breast, or breast and ovarian cancer
Breast only 182 (97) 43 (98) 117 (99) 19 (86) 3 (100)
Both breast and/or ovarian 5 (3) 1 (2) 1 (1) 3 (14) 0 (0)
Bilateral breast cancer 25 (13) 6 (14) 15 (13) 4 (18) 0 (0)
Family history of breast and ovarian cancer in pedigree
1 case (no family history) a73 (39) 24 (54) 40 (34) 8 (36) 1 (33)
2 cases 76 (41) 13 (30) 54 (46) 9 (41) 1 (33)
3 cases 24 (13) 4 (9) 17 (14) 2 (9) 0 (0)
≥ 4 cases 14 (7) 3 (7) 7 (6) 3 (14) 1 (33)
A total of 187 breast cancer patients were analysed for mutations in BRCA1 and BRCA2 by DNA sequencing and multiple ligation dependent 
probe amplification (MLPA) analysis. Table 1 shows the distribution of patients according to their self-declared ethnicity, personal history of breast 
and ovarian cancer, and family history of breast and ovarian cancer in first- and second-degree relatives. aNotably, the 73 individuals with no family 
history of breast and ovarian cancer were included in the study because they had either early age of onset of breast cancer (≤ 40 years of age: 45 
individuals; 41 to 55 years of age: nine individuals), bilateral breast cancer (16 individuals), both breast and ovarian cancer (one individual) or 
family history of prostate cancer in the third degree (three individuals).Breast Cancer Research    Vol 10 No 4    Thirthagiri et al.
Page 4 of 12
(page number not for citation purposes)
tional affected member, 19 with two additional affected mem-
bers and 11 with three or more additional affected members).
We conducted full sequence analysis of the BRCA1  and
BRCA2 genes in 187 women (Table 1). Of these: 73 had no
significant family history of breast or ovarian cancer in first- or
second-degree relatives (45 of whom developed breast can-
cer ≤ 40 years old, nine of whom developed breast cancer
between 41 and 55 years old; one had both breast and ovar-
ian cancer, 16 had bilateral breast cancer and two had a family
history of prostate cancer); and 114 had two or more cases of
breast or ovarian cancer in first- or second-degree relatives.
Mutation detection led to the discovery of 27 deleterious
mutations in 28 breast cancer patients (14 in BRCA1 and 13
in BRCA2; Table 2). Notably, 14 of these mutations were
novel (five in BRCA1 and eight in BRCA2) and one mutation
in BRCA2 was found in two unrelated families. In addition, we
identified 47 sequence variants of unknown clinical signifi-
cance (16 in BRCA1 and 31 in BRCA2), of which eight were
found to occur in more than one unrelated family (Table 3). Of
these, 26 sequence variants were novel (nine in BRCA1 and
17 in BRCA2). Eleven sequence variants (two in BRCA1 and
nine in BRCA2) may be potentially damaging based on
sequence conservation and Grantham score, and five
sequence variants are unlikely to be clinically relevant.
Table 4 shows that the majority of mutations in the Indian sub-
group were BRCA1 mutations, whereas the majority of the
mutations in the Malay subgroup were BRCA2 mutations, and
there were an equal number of mutations in both genes among
the Chinese subgroup. One possible explanation for the
higher incidence of BRCA1 mutations in the Indian subgroup
is that there was a high proportion of women with both breast
and ovarian cancer in this subgroup compared with the Chi-
nese or Malay subgroups (14% of total, compared with 1 to
2% among the Chinese and Malay; Table 1) and it is clear from
other studies that BRCA1 mutations confer a higher pene-
trance to ovarian cancer [22]. By contrast, the reason for the
higher prevalence of BRCA2 mutations among the Malays is
unclear.
Clinical presentation of breast cancer
The mean age of diagnosis of all women analysed was 43.8
years (range 22 to 78 years), and the mean age of diagnosis
was 40.3 years for BRCA1-positive (range 28 to 57 years),
43.6 years for BRCA2-positive (range 34 to 59 years) and
44.2 years for BRCA-negative women (range 22 to 78 years)
(Table 5 and 6). This is comparable to data from a large study
of 10,000 individuals in the USA [6], where individuals with
BRCA1 mutations had a significantly younger age at diagno-
sis (40 years) than those with BRCA2 (41 years).
Table 5 shows the pathological characteristics of breast can-
cer arising in BRCA1 and BRCA2 deleterious mutation carri-
ers. Consistent with other studies [23], the majority of BRCA1
tumours are high grade and negative for the oestrogen,
progesterone and HER2 receptors. By contrast, the BRCA2
tumours arise with various status for the oestrogen, progester-
one and HER2 receptor.
Prediction of BRCA1/BRCA2 carrier status based on risk 
factors
Table 7 shows the likelihood of having a BRCA1 or BRCA2
deleterious mutation, based on the personal and family history
of the individual. We found that the best predictive factors for
the presence of a BRCA1 or BRCA2 mutation are families
with at least two cases of breast cancer, at least one of which
occuring before the age of 50 (p = 0.0335), and families with
a history of both breast and ovarian cancer (p < 0.0001). Nota-
bly, of the 15 breast cancer patients with personal or family
history of ovarian cancer, six had mutations in BRCA1 and two
in BRCA2. In addition, of the 14 BRCA1 carriers and 14
BRCA2  carriers identified in this study, five had bilateral
breast cancer (one synchronous and four metachronous). The
mean time interval between surgery for the first primary cancer
and the second occurrence in the contralateral breast was 9.8
years (range four to 24 years). However, the association
between bilaterality and BRCA mutation status was not statis-
tically significant (p = 0.45). Taken together, the data suggests
that the presence of two or more breast cancers with at least
one case under the age of 50, and ovarian cancer at any age
are significant predictors for the presence of a BRCA1 or
BRCA2 mutation.
Risk prediction models (BOADICEA) and scoring 
methods (Manchester Scoring System)
Using receiver operating curves (Figure 1), we evaluated the
accuracy of using the Manchester Scoring System empirical
method compared with the BOADICEA risk-prediction models
to discriminate between those families that have a BRCA
mutation and those that do not (Table 8). The classifications
based on Manchester Score System and BOADICEA are sim-
ilar for BRCA1, but significantly different for BRCA2, which
BOADICEA did not predict accurately. In terms of discriminat-
ing between those with and without a mutation, the areas
under the receiver operating curves, a common measure of the
adequacy of a quantitative predictive algorithm, are 0.74 (95%
confidence interval [CI] = 0.67 to 0.81) and 0.82 (95% CI =
0.75 to 0.88) for BRCA1, and 0.82 (95% CI = 0.75 to 0.88)
and 0.56 (95% CI = 0.48 to 0.64) for BRCA2, for Manchester
Score System and BOADICEA, respectively (Table 8).
The probability of identifying a mutation was 66% (96 of 145),
10% (15 of 145), 9.7% (14 of 145), 6.2% (nine of 145) and
7.6% (11 of 145), at ranges of scores 4 to 14, 15 to 16, 17 to
20, 21 to 24 and 25 and above by the Manchester Scoring
System. Our analysis also indicated that a cut-off at a com-
bined Manchester score of 15 seems optimal as a threshold
(sensitivity of 72%, specificity of 74%, positive-predictiveAvailable online http://breast-cancer-research.com/content/10/4/R59
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value of 37% and negative-predictive value of 93%). At a com-
bined score of 18, the sensitivity was 56%, specificity was
84%, positive-predictive value was 42% and negative-predic-
tive value was 90%.
For a combined score of 0.10 or above using BOADICEA, we
observed sensitivity of 40%, specificity of 85%, positive-pre-
dictive value of 36% and negative-predictive value of 87%.
The total number of cases predicted by the Manchester Scor-
ing System was eight BRCA1 mutation carriers, nine BRCA2
mutation carriers and 17 mutation carriers in total (using the
probabilities listed [20,21]), and by BOADICEA was nine
BRCA1 mutation carriers, five BRCA2 mutation carriers and
14 mutation carriers in total. This was compared with the
observed numbers of 14 BRCA1, 11 BRCA2 and 25 total
carriers (three BRCA2 carriers were among the 42 individuals
excluded in the analysis because they had a single case of
breast cancer and did not have any family history of cancer in
the family). This suggests that both the Manchester Scoring
System and BOADICEA methods underpredicted the proba-
bility of having a mutation in BRCA1 or BRCA2 in our cohort.
Table 2
Deleterious mutations including frame-shift, nonsense and splice site deleterious mutations identified in Malaysian breast cancer 
patients
No. Exon Nucleotide change AA change Reported Family (No.) Ethnicity
1 BRCA1 21 8 0  d e l AS T O P  2 2 Novel 1I n d i a n
2 2 185 delAG STOP 39 Ashkenazi Jews, others 1 Indian
3 2 185 insA STOP 40 Caucasian, European 1 Chinese
4 8 589 delCT STOP 157 Caucasian, Caribbean 1 Chinese
5 11 1100 delAT STOP 328 Caucasian, Chinese [10,16] 1 Chinese
6 11 1173 G>T E352X Caucasian 1 Indian
7 11 1323 G>T E402X Novel 1 Malay
8 11 3889 delAG STOP1265 Various 1 Chinese
9 13 4377 C>T Q1420X Caucasian, African-American 1 Chinese
10 20 5370 C>T R1751X Various 1 Indian
11 IVS 3+1 G>T Novel 1 Chinese
12 IVS 3+2 delT Novel 1 Chinese
13 IVS 4-1G>C Novel 1I n d i a n
14 IVS 5-12 A>G Various 1 Chinese
1 BRCA2 34 9 0  d e l C TS T O P  9 9 Novel 2 Malay
2 10 1184 insA STOP 326 Caucasian 1 Chinese
3 10 2001 del4 STOP 612 Caucasian 1 Chinese
4 11 2699 del6 STOP 824 Novel 1 Malay
5 11 2864 delCT STOP 879 Novel 1 Chinese
6 11 4265 delCT STOP 1350 Filipino 1 Malay
7 11 6195 insA STOP 2002 Novel 1 Malay
8 11 6553 delGT STOP 2109 Novel 1 Chinese
9 11 6901 delA STOP 2228 Novel 1 Chinese
10 11 6943 G>T E2239X Novel 1 Chinese
11 22 9097 C>T Q2957X Novel 1I n d i a n
12 23 9326 insA STOP 3042 Various 1 Chinese
13 IVS 17+1 G>A Caucasian 1 ChineseBreast Cancer Research    Vol 10 No 4    Thirthagiri et al.
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Table 3
Missense and intervening sequence variants identified
No. Exon Nucleotide change AA change Reported Family (No.) Mutation classification Ethnicity
BRCA1 1 7 491 C>A I124I Novel 1 Benign? Malay
2 9 690 G>A V191I Various 2 Benign? Chinese
3 11 873 C>T R252C Novel 1 Deleterious? Malay
4 11 914 T>C S265S Novel 1 Benign? Chinese
5 11 1155 C>T P346S Asian 2 Benign? Chinese
6 11 2405 A>T R762S Chinese [8] 1 Benign? Malay
7 11 2685 T>C Y856H Chinese 6 Benign? Chinese
8 11 2845 A>T N909I Chinese 1 Benign? Chinese
9 11 2858 T>A N913K Novel 1 Benign? Chinese
10 11 3050 A>G P977P Novel 1 Benign? Chinese
11 11 3781 A>C E1221A Novel 1 Benign? Chinese
12 11 3922 A>G N1268S Novel 1 Benign? Malay
13 16 5011 G>A S1631N Novel 1 Benign? Chinese
14 24 5623 G>A R1835Q Novel 1 Benign? Malay
15 IVS 1-10 T>C Various 1 Not clinically relevant [43] Malay
16 IVS 12-10 G>A Various 1 Deleterious? Indian
BRCA2 1 3 443 A>G N72S Novel 1 Benign? Chinese
2 5 668 A>G Q147R Asian, various 2 Benign? 1 Malay, 1 Chinese
3 10 1171 T>A C315S Asian 2 Benign? Chinese
4 10 1503 A>G E425E Novel 1 Benign? Chinese
5 10 1590 A>G K454K Novel 3 Benign? Chinese
6 10 1828 G>A E534K Novel 1 Deleterious? Malay
7 10 1872 G>A Q548Q Various 1 Benign? Chinese
8 10 1875 G>A K549K Novel 1 Benign? Chinese
9 10 2053 C>G Q609E Novel 1 Benign? Malay
10 11 2906 A>G Q893R Novel 1 Benign? Malay
11 11 3648 T>C S1140S Chinese [8] 1 Benign? Chinese
12 11 3673 A>G M1149V Asian, various 3 Benign? 2 Malay, 1 Chinese
13 11 3903 A>G T1225T Novel 1 Benign? Malay
14 11 4010 C>G S1261C Novel 1 Deleterious? Malay
15 11 4806 A>G T1526T Novel 1 Benign? Other
16 11 5395 A>C T1723P Novel 1 Benign? Malay
17 11 5540 G>A G1771D Various 1 Not clinically relevant [BIC] Malay
18 11 5863 G>A E1879K Caucasian 1 Benign? Indian
19 11 6013 A>G I1929V Asian, various 1 Not clinically relevant [BIC] Chinese
20 11 6550 C>T R2108C Various 3 Benign? 2 Malay, 1 Chinese
21 12 7157 C>A T2310N Novel 1 Deleterious? Indian
22 17 8169 A>C L2647L Novel 1 Benign? MalayAvailable online http://breast-cancer-research.com/content/10/4/R59
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Discussion
This study provides important data on the prevalence and
spectrum of mutations in BRCA1 and BRCA2 in the multi-eth-
nic population of Malaysia. This key information was then cou-
pled with the family history of cancer and selection criteria to
determine the optimal strategy for clinical genetic testing in
this population, keeping in mind that this service is not yet
available in the national health care system and that it is nec-
essary to target interventions at high-risk individuals who have
the most health benefits to gain from available preventive and
risk-reduction strategies.
BRCA1 and BRCA2 mutation spectrum and prevalence
Of the 27 deleterious mutations identified, 13 mutations have
never been previously reported in any other population. Two
groups studying BRCA  mutations in Singapore, where the
population is also multi-ethnic but in different proportions (Chi-
nese 77%, Malays 14% and Indians 8%), reported seven
mutations in BRCA1 that were not observed in our cohort [24-
27]. One mutation, c.2845insA in BRCA1, was recently
reported to have a founder effect among the Malay population
in Singapore [25,28,29], but this was not found in 44 Malays
in our study.
We did not identify any mutations that occur with high fre-
quency in Asians. Four mutations that have previously been
reported in Asians: BRCA1 589delCT in at least four families
from Southern China [30], BRCA1 1100delAT in families from
Shanghai [16], BRCA2 4265delCT in at least three families
from the Philippines [31] and BRCA2 2699del6 in two fami-
lies from Indonesia [32], were also found in our cohort but
these are unlikely to be common enough to warrant specific
testing. Given the genetic diversity of the Asian populations, it
is unlikely that screening for a panel of founder mutations will
be as effective in this population as is the case for the
Ashkenazi Jewish [33] or Icelandic [34] populations.
We found that BRCA2 may play an important role in genetic
susceptibility among the small numbers of Malays in this
cohort. Similar associations have been reported among the Fil-
ipinos and Japanese [31,35]. However, the reason for a higher
proportion of BRCA2 mutations over BRCA1 mutations is not
known, but may reflect cohort selection, genetic drift, or a pos-
sible prevalence of a modifying genetic or environmental factor
that modifies the penetrance of BRCA1 or BRCA2 among
Malays. Further studies using larger cohorts of Malay individu-
als are needed to address these possibilities.
23 18 8415 G>T K2729N Asian, various 1 Not clinically relevant [44] Chinese
24 19 8584 G>A A2786T Novel 1 Deleterious? Chinese
25 21 8930 G>A G2901D Asian 1 Deleterious? Chinese
26 23 9332 A>G Y3035C Caucasian 1 Deleterious? Chinese
27 23 9334 C>G Q3036E Novel 1 Benign? Chinese
28 27 10135 A>T S3303C Novel 1 Deleterious? Other
29 27 10462 A>G I3412V Various 1 Not clinically relevant [45] Chinese
30 IVS 2-7T>A Caucasian 1 Deleterious? Malay
31 IVS 7-10 insT Novel 1 Deleterious? Other
Mutation classification was made based on published studies and analysis using PolyPhen. BIC, Breast Cancer Information Core.
Table 3 (Continued)
Missense and intervening sequence variants identified
Table 4
Incidence of BRCA1 and BRCA2 deleterious mutations, by race/ethnicity
Ethnicity Total families Families with deleterious mutation Families with unclassified variant
BRCA1 BRCA2 BRCA1 BRCA2
Malay 44 1 5 6 14
Chinese 118 8 8 15 18
Indian 22 5 1 1 2
Others 30 0 0 3
Total 187 14 14 22 37Breast Cancer Research    Vol 10 No 4    Thirthagiri et al.
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In addition to the clearly deleterious protein-truncating muta-
tions, a number of unclassified sequence variants were
detected by sequencing. Of these, nine of 16 in BRCA1
(56%) and 17 of 31 in BRCA2 are novel (55%), and several
of the remainder have only been described in Asian women. It
is likely that the majority of these sequence variants have no
clinical relevance, and the few that are likely to be deleterious
are unlikely to change the basic conclusions of this study. We
are conducting further analyses using established methods
Table 5

















No. of cases 
(Breast 
cancer ≤ 50)
ER PR HER2 Grade
BRCA1 180 delA STOP 22 55 2 43 1 - - - 2 IDC
185 delAG STOP 39 33 1 33 1 - - - 3 IDC
185 insA STOP 40 57 7 44 4 NA NA NA NA IDC
589 delCT STOP 157 45 3 41 3 - - - NA IDC
1100 delAT STOP 328 28 2 28 1 - - - 3 IDC
1173 G>T E352X 45 3 45 1 - - - 2 IDC
1323 G>T E402X 34 3 31 2 NA NA NA NA Sarcoma
3889 delAG STOP1265 47 3 47 2 - NA + NA DCIS/IDC
4377 C>T Q1420X 39 2 45 2 - - +/- 3 IDC
5370 C>T R1751X 31 5 38 3 NA NA NA NA NA
IVS 3+1 
G>T
46 2 47 2 - NA + NA IDC
IVS 3+2 
delT
32 2 56 1 - NA - 2 IDC
IVS 4-1G>C 39 2 48 1 NA NA NA NA IDC
IVS5-12 
A>G
33 1 33 1 - - - 3 IDC
BRCA2 490 delCT STOP 99 39 2 56 1 - - - 2 IDC
490 delCT STOP 99 51 4 45 3 + + - NA ILC
1184 insA STOP 326 34 1 34 1 + + - 2 IDC
2001 del4 STOP 612 37 1 37 1 + - + 3 IDC
2699 del6 STOP 824 41 2 57 1 + NA NA 2 IDC
2864 delCT STOP 879 40 1 40 1 - NA NA 3 IDC
4265 delCT STOP 1350 55 4 44 3 + + - 2 IDC
6195 insA STOP 2002 42 3 46 2 NA NA NA NA NA
6553 delGT STOP 2109 59 3 49 1 + NA - 2 IDC
6901 delA STOP 2228 35 1 35 1 NA NA NA NA IDC/DCIS
6943 G>T E2239X 47 2 44 2 NA NA NA NA NA
9097 C>T Q2957X 38 7 44 2 NA NA NA NA NA
9326 insA STOP 3042 56 4 49 2 - - NA NA NA
IVS 17+1 
G>A
36 2 46 1 - - - 3 IDC
ER, oestrogen receptor; PR, progesterone receptor; AA, amino acid; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive 
lobular carcinoma.Available online http://breast-cancer-research.com/content/10/4/R59
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[36-38] to better understand the clinical significance of these
sequence variants in our cohort.
Predicting BRCA1- and BRCA2-positive family status in 
Asia
As BRCA1 and BRCA2 mutation testing is expensive, any
ability to determine the probability that a specific family may
benefit is an important issue. Several tools have been devel-
oped to help clinicians in predicting the probability of carrying
a BRCA1 or BRCA2 mutation based on the familial history of
breast and/or ovarian cancer and all tools have been based on
populations where the age-standardised rate for breast cancer
has been significantly higher than that reported in Malaysia (80
to 100 per 100,000 compared with 30 to 50 per 100,000 in
Malaysia).
The Manchester Scoring System is perhaps the easiest of
these prediction tools to use, and to determine whether the
likelihood of identifying a mutation in a family reaches the 10%
threshold for either BRCA1 or BRCA2. This model is does not
require computer implementation. However, given that the
Manchester Scoring System was devised using data from the
Manchester region in northwest England, it is unclear whether
it would be as effective in populations with different demo-
graphics, such as that in many Asian countries. Our analysis
indicated that a cut-off at a combined Manchester score of 15
seems optimal as a threshold (sensitivity of 72%, specificity of
74%, negative-predictive value of 93%) but with a low posi-
tive-predictive value (37%). Notably, for the same cut-off of 15
among the Danish [39], the sensitivity was 84%, but the spe-
cificity was lower at 44%. The optimal cut-off appears to be
lower for our population compared with studies in Australians
[40] and French-Canadians in Canada [41], where compara-
ble sensitivity and specificity (86% and 82% respectively in
the Australians, and 72% and 64% respectively in the Canadi-
ans) were obtained with a higher score of 18. Taken together,
our data suggests that in populations such as ours, where the
Table 6
Summary of family characteristics and pathological characteristics of breast cancers of individuals with deleterious BRCA1 and 
BRCA2 mutations
Overall BRCA1 BRCA2 Non-BRCA
Age of onset 22 to 78 28 to 57 34 to 59 22 to 78
Average age of onset (years) 41.9 40.3 43.6 44.2
Total no. of breast and ovarian cancers in family 1 to 7 1 to 7 1 to 7 1 to 6
Average no. of breast and ovarian cancers in family 1.9 2.7 2.6 1.8
No. of cases of breast cancer <50 0 to 4 1 to 3 1 to 3 0 to 4
Average no. of cases of breast cancer <50 1.1 1.6 1.5 1.0
% with ER-negative tumours 48% 100% 40% 45%
Table 7
Likelihood of having a BRCA1 or BRCA2 deleterious mutations
Personal history Family history Total BRCA1 positive BRCA2 positive BRCA positive BRCA positive
Number Number Number %
Breast cancer <50 years Nil 61 2 3 5 8.2
Breast cancer <50 years 1 breast cancer <50 years 29 1 3 4 13.8
Breast cancer ≥ 50 years 1 breast cancer <50 years 13 1 0 1 7.7
Breast cancer at any age ≥ 2 breast cancer <50 years 7 1 0 1 14.3
Breast cancer at any age ≥ 3 breast cancer at any age 9 0 3 3 33.3
Breast cancer at any age ≥ 1 ovarian cancer at any age 10 4 1 5 50.0
Breast and ovarian cancer Any 5 2 1 3 60.0
Bilateral breast cancer Any 25 4 1 5 20.0Breast Cancer Research    Vol 10 No 4    Thirthagiri et al.
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overall incidence of breast and ovarian cancers is lower than
that in Caucasian populations, family history is more significant
therefore giving a higher specificity at a lower score.
In contrast, BOADICEA requires computation and is more dif-
ficult to implement in a clinical setting that is not familiar with
risk prediction and genetic testing. Nevertheless, the strength
of the model relies in its ability to compute extensive family his-
tory, and mutations in other genes relevant to breast cancer,
such as CHEK2, to calculate the probability of carrying a
mutation in the BRCA genes. In our analysis, a cut-off proba-
bility of 10% or higher yielded comparable specificity albeit
with compromised sensitivity (85% and 40% respectively) to
that reported in an analysis of 300 non-Ashkenazi Jewish, pre-
dominantly Caucasian families [42] (specificity 68% and sen-
sitivity 73% respectively).
We found that both the Manchester Scoring System and
BOADICEA underestimated the number of mutation carriers in
our cohort. The most likely explanation, which is consistent
with other studies, may be that both methods underestimate
the number of carriers in families with insignificant family his-
tory [42], that is both methods underestimate the exceptional
nature of the families, within the context of a lower population
rate of breast cancer. In addition, the underestimate may be
more significant for BRCA2 in BOADICEA because the allelic
frequency of BRCA2 may be different in the ethnic population
we have studied compared with Caucasian populations, and
may be because BRCA2 may have a different penetrance in
this population.
Overall, in this typically Asian cohort where 80% (149 of 187)
of the breast cancer patients had no or only a single first- or
second-degree relative with breast cancer or ovarian cancer,
Figure 1
Receiver Operating Characteristic curves for Manchester Scoring and BOADICEA predictions of the probability of carrying a BRCA1 or BRCA2  mutation Receiver Operating Characteristic curves for Manchester Scoring and BOADICEA predictions of the probability of carrying a BRCA1 or BRCA2 
mutation.
Table 8
The sensitivities, specificities, and positive and negative predictive values calculated with a Manchester Scoring System cut-off 
score of ≥ 10 for each gene and ≥ 15 combined, and for BOADICEA score of ≥ 0.10 for each gene and ≥ 0.10 combined (ie, 10% 
probability of carrying a deleterious mutation)
Manchester Scoring System BOADICEA
BRCA1 BRCA2 Combined BRCA1 BRCA2 Combined
Area under the receiver operating curves 0.74 0.82 0.80 0.82 0.56 0.73
Standard error 0.078 0.079 0.06 0.070 0.093 0.061
95% CI 0.67 – 0.81 0.75 – 0.88 0.72 – 0.86 0.75 – 0.88 0.48 – 0.64 0.65 – 0.80
P valuea 0.0018 0.0001 0.0001 0.0001 0.507 0.0001
Sensitivity 57% 55% 72% 57% 9% 40%
Specificity 76% 87% 74% 93% 93% 85%
Positive-predictive value 20% 25% 37% 47% 10% 36%
Negative-predictive value 94% 96% 93% 95% 93% 87%
aP value is the probability that the sample area under the ROC curve is found when in fact, the true area under the ROC curve is 0.5 (i.e. null 
hypothesis: Area = 0.5).Available online http://breast-cancer-research.com/content/10/4/R59
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15% of women carried deleterious mutations in BRCA1 or
BRCA2. This suggests that a family history as reported by an
individual who carries a mutation in BRCA1 or BRCA2 may be
neither dramatic nor obvious. Indeed, in a study of 10,000 indi-
viduals in the USA, up to 13% of individuals with a single first-
or second-degree relative with early-onset breast cancer or
ovarian cancer, carried deleterious mutations [6]. This sug-
gests that careful evaluation of paternal as well as maternal
family history is required, especially in women diagnosed with
breast cancer before age 50 years or ovarian cancer at any
age, to enable the appropriate identification and counselling of
individuals at risk of carrying mutations in BRCA1  and
BRCA2. We believe that identification of individuals at risk is
particularly significant in Asia because the problem of limited
family structure is not uncommon, in part because of loss of
family information from migration, and there remains significant
stigma in talking about cancer [9].
Conclusion
Taking into consideration the recommendations described
above and our findings, it seems reasonable in a clinical set-
ting to offer individuals with a personal or family history of can-
cer testing if they have a combined Manchester score of 15 or
above. Lower thresholds could be used when resources
become available and where the judgement of health care pro-
fessionals involved in familial cancer clinics indicates. Our
study underscores the need for larger collaborative studies
among non-Caucasian populations to validate the role of
genetic testing, the use of risk-prediction models and the role
of risk-reducing strategies in ensuring that the other popula-
tions in the world may also benefit from the genomics and
genetics era.
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